公开(公告)号：US10881726B2

公开(公告)日：2021-01-05

申请号：US16336732

申请日：2017-10-05

申请人： The Governors of the University of Alberta ,  Helmholtz Center for Infection Research

发明人： Michael Houghton ,  Abdolamir Landi ,  Carlos A. Guzman ,  Thomas Ebensen ,  Darren Hockman ,  John L. Law ,  Michael Logan

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  A61K31/675 ,  A61K39/095 ,  A61K39/29 ,  A61P31/14 ,  A61P37/04 ,  C07K14/005 ,  C01F11/02 ,  C07D323/00 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C12N15/86

摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

公开(公告)号：US12048742B2

公开(公告)日：2024-07-30

申请号：US16978486

申请日：2019-03-14

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Abdolamir Landi ,  Michael Logan ,  John L. Law ,  Chao Chen ,  Darren Hockman

IPC分类号： A61K39/29 ,  A61K39/00 ,  A61P31/14 ,  A61P37/04

CPC分类号： A61K39/29 ,  A61P31/14 ,  A61P37/04 ,  A61K2039/55505 ,  C12N2770/24222 ,  C12N2770/24234

摘要： The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.

公开(公告)号：US20210100895A1

公开(公告)日：2021-04-08

申请号：US17122578

申请日：2020-12-15

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC分类号： A61K39/29 ,  A61K39/12 ,  A61P37/04 ,  A61P31/14 ,  A61P31/04 ,  A61K39/295 ,  C12N15/861

摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US20190231867A1

公开(公告)日：2019-08-01

申请号：US16336732

申请日：2017-10-05

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Abdolamir Landi

IPC分类号： A61K39/29 ,  A61K39/39 ,  A61P31/14 ,  A61P37/04 ,  C07D323/00 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C01F11/02 ,  C12N15/86

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55588 ,  A61P31/14 ,  A61P37/04 ,  C01F11/02 ,  C07D323/00 ,  C07K14/005 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C12N15/86 ,  C12N2770/24234

摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

公开(公告)号：US20190209677A1

公开(公告)日：2019-07-11

申请号：US16334683

申请日：2017-09-21

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Abdolamir Landi ,  Michael Logan ,  John L. Law ,  Darren Hockman ,  Chao Chen

IPC分类号： A61K39/29

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55544 ,  A61K2039/70 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2770/24234

摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.

公开(公告)号：US20180209992A1

公开(公告)日：2018-07-26

申请号：US15922012

申请日：2018-03-15

申请人： The Governors of the University of Alberta ,  Medizinische Hochschule Hannover

发明人： Abdolamir Landi ,  Michael Houghton ,  D. Lorne Tyrrell ,  Tim Lankisch ,  Tobias Weismueller ,  Michael Manns

IPC分类号： G01N33/68 ,  A61K45/00

CPC分类号： G01N33/6893 ,  A61K45/00 ,  G01N33/6827 ,  G01N2333/521 ,  G01N2333/523 ,  G01N2333/5443 ,  G01N2333/916 ,  G01N2800/085 ,  G16B40/00 ,  G16H50/20 ,  G16H50/30 ,  Y02A90/22 ,  Y02A90/24 ,  Y02A90/26

摘要： The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

公开(公告)号：US20170153251A1

公开(公告)日：2017-06-01

申请号：US15357841

申请日：2016-11-21

申请人： The Governors of the University of Alberta ,  Medizinische Hochschule Hannover

发明人： Abdolamir Landi ,  Michael Houghton ,  D. Lorne Tyrrell ,  Tim Lankisch ,  Tobias Weismueller ,  Michael Manns

IPC分类号： G01N33/68 ,  A61K45/00

CPC分类号： G01N33/6893 ,  A61K45/00 ,  G01N33/6827 ,  G01N2333/521 ,  G01N2333/523 ,  G01N2333/5443 ,  G01N2333/916 ,  G01N2800/085 ,  G06F19/00 ,  G06F19/24 ,  G16H50/20 ,  G16H50/30 ,  Y02A90/22 ,  Y02A90/24 ,  Y02A90/26

摘要： The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

公开(公告)号：US09535071B2

公开(公告)日：2017-01-03

申请号：US14423998

申请日：2013-09-06

申请人： The Governors of the University of Alberta ,  Medizinische Hochschule Hannover

发明人： Abdolamir Landi ,  Michael Houghton ,  D. Lorne Tyrrell ,  Tim Lankisch ,  Tobias Weismueller ,  Michael Manns

IPC分类号： C40B30/04 ,  G01N33/48 ,  G01N33/68 ,  G06F19/24 ,  G06F19/00

CPC分类号： G01N33/6893 ,  A61K45/00 ,  G01N33/6827 ,  G01N2333/521 ,  G01N2333/523 ,  G01N2333/5443 ,  G01N2333/916 ,  G01N2800/085 ,  G06F19/00 ,  G06F19/24 ,  G16H50/20 ,  G16H50/30 ,  Y02A90/22 ,  Y02A90/24 ,  Y02A90/26

摘要： The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

摘要翻译： 本公开提供了用于促进受试者中炎症性肝病诊断的方法和组合物。 方法和组合物通常涉及单独或与嗜酸细胞活化趋化因子-1（E1）水平以及任选地与CCL22水平以及进一步任选的IL15水平检测嗜酸细胞活化趋化因子-3（E3）水平。 这些水平可以用于促进自身免疫性肝炎（AIH），原发性胆汁性肝硬化（PBC）和原发性硬化性胆管炎（PSC）中的至少一种的肝脏疾病的诊断，和/或促进AIH， PBC和PSC。 本公开的方法和组合物还用于促进受试者的治疗决定。

公开(公告)号：US12042536B2

公开(公告)日：2024-07-23

申请号：US18099035

申请日：2023-01-19

申请人： The Governors of the University of Alberta ,  Helmholtz Center for Infection Research

发明人： Michael Houghton ,  Abdolamir Landi ,  Carlos A. Guzman ,  Thomas Ebensen ,  Darren Hockman ,  John L. Law ,  Michael Logan

IPC分类号： A61K39/29 ,  A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  A61P31/14 ,  A61P37/04 ,  C01F11/02 ,  C07D323/00 ,  C07K14/005 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C12N15/86

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K39/39 ,  A61P31/14 ,  A61P37/04 ,  C01F11/02 ,  C07D323/00 ,  C07K14/005 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C12N15/86 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55588 ,  C12N2770/24234

摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

公开(公告)号：US20240238413A1

公开(公告)日：2024-07-18

申请号：US18391501

申请日：2023-12-20

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Abdolamir Landi ,  John L. Law

IPC分类号： A61K39/29 ,  A61K39/00 ,  A61K39/39 ,  A61P37/04

CPC分类号： A61K39/29 ,  A61K39/39 ,  A61P37/04 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/55577

摘要： The present disclosure provides immunogenic compositions comprising one or more T-cell epitope polypeptides, or a fusion polypeptide comprising two or more T-cell epitope polypeptides. The present disclosure provides a method for inducing an immune response to hepatitis C virus in an individual, the method comprising administering to the individual an immunogenic composition of the present disclosure.